News
NeurAxis Announces New Medical Policy Coverage in North Dakota
CARMEL, Ind., April 23, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the...
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
CARMEL, Ind., April 09, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the...
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
CARMEL, Ind., April 01, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial...
NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry
CARMEL, Ind., March 27, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the...
NeurAxis Announces Highmark BCBS Policy Coverage
CARMEL, Ind., March 11, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt...
NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage
CARMEL, Ind., March 04, 2024 -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced receipt...
NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference
CARMEL, Ind., Feb. 27, 2024 -- NeurAxis, Inc. (NYSE American: NRXS), ("NeurAxis," or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced that...
NeurAxis Appoints Timothy Henrichs as Chief Financial Officer
CARMEL, Ind., Jan. 31, 2024 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the...
NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer
CARMEL, Ind., Dec. 20, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today issued a letter to...
NeurAxis Reports Third Quarter 2023 Financial Results
CARMEL, Ind., Nov. 20, 2023 -- NeurAxis, Inc. (NYSE American: NRXS) ("NeurAxis" or the "Company"), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial...